| Mr Charles Ray Gosnell, MD | |
|
497 West Lott, Buffalo, WY 82834-1609 | |
| (307) 684-2228 | |
| (307) 684-5385 |
| Full Name | Mr Charles Ray Gosnell |
|---|---|
| Gender | Male |
| Speciality | Radiology - Diagnostic Ultrasound |
| Location | 497 West Lott, Buffalo, Wyoming |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1477531598 | NPI | - | NPPES |
| 312761 | Other | WY | BLUE CROSS |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2085R0202X | Radiology - Diagnostic Radiology | 3668A (Wyoming) | Primary |
| 2085U0001X | Radiology - Diagnostic Ultrasound | 3668A (Wyoming) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Mr Charles Ray Gosnell, MD 497 West Lott, Buffalo, WY 82834-1609 Ph: (307) 684-2228 | Mr Charles Ray Gosnell, MD 497 West Lott, Buffalo, WY 82834-1609 Ph: (307) 684-2228 |
News Archive
Canadian researchers have shown that commonly used household cleaning products could be making children overweight by causing changes in their gut microflora.
Astellas today announced it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration seeking approval for isavuconazole for the treatment of invasive aspergillosis and invasive mucormycosis (also known as zygomycosis), life-threatening fungal infections predominantly occurring in immunocompromised patients.
The European market for health information exchange is diverse, with different IT vendors supporting the process of information exchange at different levels. European healthcare policies favour interoperability. This is encouraging the growth of public health information exchange programmes.
Physicians Interactive, the leading provider of online and mobile clinical resources and solutions for healthcare professionals (HCPs), today announced that its eCoupon automated voucher and coupon distribution solution is now available within the latest version of Greenway Health's PrimeSUITE electronic health record (EHR) system.
The results of the much awaited BEAUTIFUL (morBidity-mortality EvAlUaTion of the If inhibitor ivabradine in patients with CAD and left ventricULar dysfunction) trial have shown that coronary artery disease (CAD) patients with left ventricular dysfunction (LVD) and a heart rate more than 70 bpm have a significantly higher risk of cardiovascular death and other cardiovascular events and in these patients (heart rate above 70 bpm) treatment with ivabradine further reduces the risk of the most important coronary events such as fatal and non-fatal myocardial infarction and coronary revascularisation by one third, even when these patients are already receiving optimal therapy.
› Verified 9 days ago